TY - JOUR
T1 - Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia
T2 - outcomes from a large multi-center collaboration
AU - Stephens, Deborah M.
AU - Boucher, Ken
AU - Kander, Elizabeth
AU - Parikh, Sameer A.
AU - Parry, Erin M.
AU - Shadman, Mazyar
AU - Pagel, John M.
AU - Cooperrider, Jennifer
AU - Rhodes, Joanna
AU - Mato, Anthony
AU - Winter, Allison
AU - Hill, Brian
AU - Gaballa, Sameh
AU - Danilov, Alexey
AU - Phillips, Tycel
AU - Brander, Danielle M.
AU - Smith, Sonali M.
AU - Davids, Matthew
AU - Rogers, Kerry
AU - Glenn, Martha J.
AU - Byrd, John C.
PY - 2020/10/5
Y1 - 2020/10/5
N2 - Chronic lymphocytic leukemia (CLL) patients who develop Hodgkin lymphoma (HL) have limited survival. No current therapeutic standard of care exists. We conducted a multi-center retrospective study of patients with Hodgkin Transformation (HT) of CLL. Clinicobiologic characteristics, treatment type, and survival outcomes were analyzed and compared with historic case series. Ninety-four patients were identified. Median age at HT was 67 years (range, 38-85). Median time from CLL diagnosis to HT was 5.5 years (range, 0-20.2). Prior to HT, patients received a median of 2 therapies for CLL (range, 0-12). As initial therapy for HT, 61% (n=62) received ABVD-based regimens (adriamycin, bleomycin, vinblastine, and dacarbazine). Seven (7%) patients received hematopoietic cell transplantation (HCT) while in first complete remission (CR1). The median number of treatments for HT per patient was 1 (range, 0-5) with 59 (61%) patients only receiving one line of therapy. After HT, patients had a median follow-up of 1.6 years (range, 0-15.1). Two-year overall survival (OS) after HT diagnosis was 72% (95%CI 62-83%). The patients who received standard ABVD-based therapy had a median OS of 13.2 years. Although limited by small sample size, the patients who underwent HCT for HT in CR1 had a similar 2-year OS (n=7; 67%) compared to patients who did not undergo HCT for HT in CR1 (n=87; 72%; p=0.46). In this multi-center study, HT patients treated with ABVD-based regimens had prolonged survival supporting the use of these regimens as standard of care for these patients.
AB - Chronic lymphocytic leukemia (CLL) patients who develop Hodgkin lymphoma (HL) have limited survival. No current therapeutic standard of care exists. We conducted a multi-center retrospective study of patients with Hodgkin Transformation (HT) of CLL. Clinicobiologic characteristics, treatment type, and survival outcomes were analyzed and compared with historic case series. Ninety-four patients were identified. Median age at HT was 67 years (range, 38-85). Median time from CLL diagnosis to HT was 5.5 years (range, 0-20.2). Prior to HT, patients received a median of 2 therapies for CLL (range, 0-12). As initial therapy for HT, 61% (n=62) received ABVD-based regimens (adriamycin, bleomycin, vinblastine, and dacarbazine). Seven (7%) patients received hematopoietic cell transplantation (HCT) while in first complete remission (CR1). The median number of treatments for HT per patient was 1 (range, 0-5) with 59 (61%) patients only receiving one line of therapy. After HT, patients had a median follow-up of 1.6 years (range, 0-15.1). Two-year overall survival (OS) after HT diagnosis was 72% (95%CI 62-83%). The patients who received standard ABVD-based therapy had a median OS of 13.2 years. Although limited by small sample size, the patients who underwent HCT for HT in CR1 had a similar 2-year OS (n=7; 67%) compared to patients who did not undergo HCT for HT in CR1 (n=87; 72%; p=0.46). In this multi-center study, HT patients treated with ABVD-based regimens had prolonged survival supporting the use of these regimens as standard of care for these patients.
UR - http://www.scopus.com/inward/record.url?scp=85093538553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093538553&partnerID=8YFLogxK
U2 - 10.3324/haematol.2020.256388
DO - 10.3324/haematol.2020.256388
M3 - Article
C2 - 33054118
AN - SCOPUS:85093538553
VL - Online ahead of print
JO - Haematologica
JF - Haematologica
SN - 0390-6078
ER -